Medical treatment of pulmonary hypertension in adults with congenital heart disease updated and extended results from the International COMPERA-CHD Registry /

Background: Pulmonary arterial hypertension (PAH) is common in congenital heart disease (CHD). Because clinical-trial data on PAH associated with CHD (PAH-CHD) remain limited, registry data on the long-term course are essential. This analysis aimed to update information from the COMPERA-CHD registry...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Kaemmerer Ann-Sophie
Gorenflo Matthias
Huscher Doerte
Pittrow David
Ewert Peter
Pausch Christine
Delcroix Marion
Ghofrani Hossein A.
Hoeper Marius M.
Kozlik-Feldmann Rainer
Skride Andris
Staehler Gerd
Vizza Carmine Dario
Jureviciene Elena
Jancauskaite Dovile
Gumbiene Lina
Ewert Ralf
Daehnert Ingo
Held Matthias
Halank Michael
Skowasch Dirk
Klose Hans
Wilkens Heinrike
Milger Katrin
Jux Christian
Koestenberger Martin
Scelsi Laura
Brunnemer Eva
Hofbeck Michael
Ulrich Silvia
Nemes Attila
Dokumentumtípus: Cikk
Megjelent: 2021
Sorozat:CARDIOVASCULAR DIAGNOSIS AND THERAPY 11 No. 6
Tárgyszavak:
doi:10.21037/cdt-21-351

mtmt:32201288
Online Access:http://publicatio.bibl.u-szeged.hu/37317
LEADER 04377nab a2200577 i 4500
001 publ37317
005 20250724132127.0
008 250724s2021 hu o 000 eng d
022 |a 2223-3652 
024 7 |a 10.21037/cdt-21-351  |2 doi 
024 7 |a 32201288  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a eng 
100 1 |a Kaemmerer Ann-Sophie 
245 1 0 |a Medical treatment of pulmonary hypertension in adults with congenital heart disease  |h [elektronikus dokumentum] :  |b updated and extended results from the International COMPERA-CHD Registry /  |c  Kaemmerer Ann-Sophie 
260 |c 2021 
300 |a 1255-1268 
490 0 |a CARDIOVASCULAR DIAGNOSIS AND THERAPY  |v 11 No. 6 
520 3 |a Background: Pulmonary arterial hypertension (PAH) is common in congenital heart disease (CHD). Because clinical-trial data on PAH associated with CHD (PAH-CHD) remain limited, registry data on the long-term course are essential. This analysis aimed to update information from the COMPERA-CHD registry on management strategies based on real-world data. Methods: The prospective international pulmonary hypertension registry COMPERA has since 2007 enrolled more than 10,000 patients. COMPERA-CHD is a sub-registry for patients with PAH-CHD Results: A total of 769 patients with PAH-CHD from 62 specialized centers in 12 countries were included into COMPERA-CHD from January 2007 through September 2020. At the last follow-up in 09/2020, patients [mean age 45.3 +/- 16.8 years; 512 (66%) female] had either post-tricuspid shunts (n=359; 46.7%), pre-tricuspid shunts (n=249; 32.4%), complex CHD (n=132; 17.2%), congenital left heart or aortic valve or aortic disease (n=9; 1.3%), or miscellaneous CHD (n=20; 2.6%). The mean 6-minute walking distance was 369 +/- 121 m, and 28.2%, 56.0%, and 3.8% were in WHO functional class I/II, III or IV, respectively (12.0% unknown). Compared with the previously published COMPERA-CHD data, after 21 months of followup, the number of included PAH-CHD patients increased by 91 (13.4%). Within this group the number of Eisenmenger patients rose by 39 (16.3%), the number of "Non-Eisenmenger PAH" patients by 45 (26.9%). Currently, among the 674 patients from the PAH-CHD group with at least one follow-up, 450 (66.8%) received endothelin receptor antagonists (ERA), 416 (61.7%) PDE-5 inhibitors, 85 (12.6%) prostacyclin analogues, and 36 (5.3%) the sGC stimulator riociguat. While at first inclusion in the COMPERA-CHD registry, treatment was predominantly monotherapy (69.3%), this has shifted to favoring combination therapy in the current group (53%). For the first time, the nature, frequency, and treatment of significant comorbidities requiring supportive care and medication are described. Conclusions: Analyzing "real life data" from the international COMPERA-CHD registry, we present a comprehensive overview about current management modalities and treatment concepts in PAH-CHD. There was an trend towards more aggressive treatment strategies and combination therapies. In the future, particular attention must be directed to the "Non-Eisenmenger PAH" group and to patients with complex CHD, including Fontan patients. 
650 4 |a Klinikai orvostan 
700 0 1 |a Gorenflo Matthias  |e aut 
700 0 1 |a Huscher Doerte  |e aut 
700 0 1 |a Pittrow David  |e aut 
700 0 1 |a Ewert Peter  |e aut 
700 0 1 |a Pausch Christine  |e aut 
700 0 1 |a Delcroix Marion  |e aut 
700 0 1 |a Ghofrani Hossein A.  |e aut 
700 0 1 |a Hoeper Marius M.  |e aut 
700 0 2 |a Kozlik-Feldmann Rainer  |e aut 
700 0 2 |a Skride Andris  |e aut 
700 0 2 |a Staehler Gerd  |e aut 
700 0 2 |a Vizza Carmine Dario  |e aut 
700 0 2 |a Jureviciene Elena  |e aut 
700 0 2 |a Jancauskaite Dovile  |e aut 
700 0 2 |a Gumbiene Lina  |e aut 
700 0 2 |a Ewert Ralf  |e aut 
700 0 2 |a Daehnert Ingo  |e aut 
700 0 2 |a Held Matthias  |e aut 
700 0 2 |a Halank Michael  |e aut 
700 0 2 |a Skowasch Dirk  |e aut 
700 0 2 |a Klose Hans  |e aut 
700 0 2 |a Wilkens Heinrike  |e aut 
700 0 2 |a Milger Katrin  |e aut 
700 0 2 |a Jux Christian  |e aut 
700 0 2 |a Koestenberger Martin  |e aut 
700 0 2 |a Scelsi Laura  |e aut 
700 0 2 |a Brunnemer Eva  |e aut 
700 0 2 |a Hofbeck Michael  |e aut 
700 0 2 |a Ulrich Silvia  |e aut 
700 0 2 |a Nemes Attila  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/37317/1/Kaemmerer.pdf  |z Dokumentum-elérés